Key points are not available for this paper at this time.
Functional AT III assays may uncover qualitative defects missed by antigen testing; leaves open whether routine use improves thrombophilia management.
A family with a tendency to thrombosis and decreased antithrombin III (AT III) activity in plasma, but normal immunoreactive AT III is reported. 7 members of the family had the AT III defect, 4 of whom have had thrombotic episodes. The importance of biological determination of AT III when studying patients with recurrent thrombotic episodes is emphasized.
No takes yet. Share an insight, caveat, or question.
Sørensen et al. (1980) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: